Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy
HAIC combined with fruquintinib and tislelizumab may be an alternative salvage treatment for patients with MSS-CRCLM following failure of multiple-line therapy.
Authors
- Chuanxin M. Niu (ORCID: https://orcid.org/0000-0001-6013-2492)
- Kanglian Zheng (ORCID: https://orcid.org/0000-0003-2401-002X)
- Quan Bao (ORCID: https://orcid.org/0000-0002-3675-2656)
- Da Xu (ORCID: https://orcid.org/0000-0001-5084-2802)
- Wei Liu (ORCID: https://orcid.org/0000-0002-7580-034X)
- Kun Wang (ORCID: https://orcid.org/0000-0002-9778-9479)
- Xu Zhu (ORCID: https://orcid.org/0000-0002-4347-3639)
- Guangwen Cao (ORCID: https://orcid.org/0000-0002-8094-1278)
- Xiaoluan Yan
- Xiaodong Wang (ORCID: https://orcid.org/0000-0002-1045-583X)
- Baocai Xing (ORCID: https://orcid.org/0000-0002-9908-8588)
- Liang Xu
- Lijun Wang
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.3389/fonc.2024.1420956
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China